Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Specific post-marketing surveillance of garenoxacin (Geninax®) Clinical efficacy and safety of garenoxacin in the treatment of legionella pneumonia
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	non interventional
	Summary	To investigate the clinical efficacy and safety of garenoxacin (Geninax®) in patients with legionella pneumonia on retrospective approach.
Details of study	Interventional drug name	Garenoxacin 200 mg table
	Target illness	Legionella pneumonia
	Classification name (code) of the investigational drug	624 (synthetic antibacterials)
	Administration route	oral administration
	Control drug name(code/td)	-
	Classification name (code) of the investigational drug	-
	Administration route	-
	Objectives of the study	To evaluate the efficacy and safety
	Study phase	Other
	Study design	Post-marketing surveillance study
	Inclusion Criteria	Registered patients in Japanese Society of Chemotherapy the committee of evaluation of legionella pneumonia on or after May 7, 2008
	Outcome	Efficacy 1. Evaluation of therapy 2. Evaluation of preventing reactivation
	Study status	Completed
	Duration of the study	May 7, 2008 – April 30, 2010
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Data Science and Administration Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn